<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35005109</PMID><DateRevised><Year>2022</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2352-3042</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Genes &amp; diseases</Title><ISOAbbreviation>Genes Dis</ISOAbbreviation></Journal><ArticleTitle>Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease.</ArticleTitle><Pagination><StartPage>80</StartPage><EndPage>94</EndPage><MedlinePgn>80-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gendis.2021.03.007</ELocationID><Abstract><AbstractText>Infections caused by viruses are one of the foremost causes of morbidity and mortality in the world. Although a number of antiviral drugs are currently used for treatment of various kinds of viral infection diseases, there is still no available therapeutic agent for most of the viruses in clinical practice. Coumarin is a chemical compound which is found naturally in a variety of plants, it can also be synthetically produced possessing diverse biological effects. More recently, reports have highlighted the potential role of coumarin derivatives as antiviral agents. This review outlines the advances in coumarin-based compounds against various viruses including human immunodeficiency virus, hepatitis virus, herpes simplex virus, Chikungunya virus and Enterovirus 71, as well as the structure activity relationship and the possible mechanism of action of the most potent coumarin derivatives.</AbstractText><CopyrightInformation>&#xa9; 2021 Chongqing Medical University. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhoupeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medical of the State Administration of Traditional Chinese Medicine, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shanxi 710032, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Dehui</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Nursing, Army Medical University (Third Military Medical University), Chongqing 400038, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yongsheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medical of the State Administration of Traditional Chinese Medicine, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shanxi 710032, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingkai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medical of the State Administration of Traditional Chinese Medicine, School of Pharmacy, The Fourth Military Medical University, Xi'an, Shanxi 710032, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Pharmacy &amp; Drug Development Center, The Fourth Military Medical University, Xi'an, Shanxi 710032, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Genes Dis</MedlineTA><NlmUniqueID>101635967</NlmUniqueID><ISSNLinking>2352-3042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coumarin</Keyword><Keyword MajorTopicYN="N">Hepatitis virus</Keyword><Keyword MajorTopicYN="N">Human immunodeficiency virus</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Molecular mechanism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35005109</ArticleId><ArticleId IdType="pmc">PMC8720699</ArticleId><ArticleId IdType="doi">10.1016/j.gendis.2021.03.007</ArticleId><ArticleId IdType="pii">S2352-3042(21)00046-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe T., Marutani Y., Shoji I. Cytosolic DNA-sensing immune response and viral infection. Microbiol Immunol. 2019;63(2):51&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7168513</ArticleId><ArticleId IdType="pubmed">30677166</ArticleId></ArticleIdList></Reference><Reference><Citation>Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">31971553</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E., Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumlova M., Ruml T. In&#xa0;vitro methods for testing antiviral drugs. Biotechnol Adv. 2018;36(3):557&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127693</ArticleId><ArticleId IdType="pubmed">29292156</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman D.J., Cragg G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">32162523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Q.C., Gao C., Xu Z., et al. Bis-coumarin derivatives and their&#xa0;biological activities. Curr Top Med Chem. 2018;18(2):101&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">29473509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Chen W., Shen Y., Zhu B., Wang G.X. Synthesis and antiviral activity of coumarin derivatives against infectious hematopoietic necrosis virus. Bioorg Med Chem Lett. 2019;29(14):1749&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">31104994</ArticleId></ArticleIdList></Reference><Reference><Citation>Khomenko T.M., Zarubaev V.V., Orshanskaya I.R., et al. Anti-influenza activity of monoterpene-containing substituted coumarins. Bioorg Med Chem Lett. 2017;27(13):2920&#x2013;2925.</Citation><ArticleIdList><ArticleId IdType="pubmed">28501512</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca L., Agharbaoui F.E., Gitto R., et al. Rational design, synthesis and evaluation of coumarin derivatives as protein-protein interaction inhibitors. Mol Inform. 2016;35(8&#x2013;9):460&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">27546050</ArticleId></ArticleIdList></Reference><Reference><Citation>Olomola T.O., Klein R., Mautsa N., Sayed Y., Kaye P.T. Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors. Bioorg Med Chem. 2013;21(7):1964&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">23415084</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarner J. Human immunodeficiency virus: diagnostic approach. Semin Diagn Pathol. 2017;34(4):318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">28502523</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh U.M., McCormick K., van Zyl G., Mellors J.W. Future technologies for monitoring HIV drug resistance and cure. Curr Opin HIV AIDS. 2017;12(2):182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6738332</ArticleId><ArticleId IdType="pubmed">28059958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimukangara B., Varyani B., Shamu T., et al. HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing. J Virol Methods. 2017;243:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5393912</ArticleId><ArticleId IdType="pubmed">27894862</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed A.A., Tachedjian G. Why do we need new drug classes for HIV treatment and prevention? Curr Top Med Chem. 2016;16(12):1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">26459806</ArticleId></ArticleIdList></Reference><Reference><Citation>Laila U., Akram M., Shariati M.A., et al. Role of medicinal plants in HIV/AIDS therapy. Clin Exp Pharmacol Physiol. 2019;46(12):1063&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">31365763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesar G.Z., Alfonso M.G., Marius M.M., et al. Inhibition of HIV-1 reverse transcriptase, toxicological and chemical profile of Calophyllum brasiliense extracts from Chiapas, Mexico. Fitoterapia. 2011;82(7):1027&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">21723379</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiznhamer D.A., Creagh T., Ruckle J.L., et al. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials. 2002;3(6):435&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12501127</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler M.S. Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep. 2005;22(2):162&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15806196</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue H., Lu X., Zheng P., et al. Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile. J Med Chem. 2010;53(3):1397&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">20050672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Zhang Q., Guo J., et al. Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol. 2017;8:479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5515859</ArticleId><ArticleId IdType="pubmed">28769808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.T., Kashiwada Y., Huang L., Snider J., Cosentino M., Lee K.H. Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. Bioorg Med Chem. 1994;2(10):1051&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">7773621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D., Brossi A., Kilgore N., Wild C., Allaway G., Lee K.H. Anti-HIV agents. Part 55: 3'R,4'R-Di-(O)-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP), a novel anti-HIV agent. Bioorg Med Chem Lett. 2003;13(9):1575&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.Y., Xia Y., Xia P., Cosentino L.M., Lee K.H. Anti-AIDS agents. 31. Synthesis and anti-HIV activity of 4-substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) thiolactone analogs. Bioorg Med Chem Lett. 1998;8(12):1483&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.Y., Xia Y., Xia P., Brossi A., Cosentino L.M., Lee K.H. Anti-AIDS agents part 41: synthesis and anti-HIV activity of 3',4'-di-o-(-)-camphanoyl-(+)-cis-khellactone (DCK) lactam analogues. Bioorg Med Chem Lett. 2000;10(10):1003&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843202</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Takeuchi Y., Cosentino L.M., McPhail A.T., Lee K.H. Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone analogues. J Med Chem. 2001;44(5):664&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11262077</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Takeuchi Y., Cosentino L.M., Lee K.H. Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents. J Med Chem. 1999;42(14):2662&#x2013;2672.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411486</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Takeuchi Y., Cosentino L.M., Lee K.H. Anti-AIDS agents. 33. Synthesis and anti-HIV activity of mono-methyl substituted&#xa0;3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues. Bioorg Med Chem Lett. 1998;8(16):2151&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873504</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Allaway G., Wild C., Kilgore N., Lee K.H. Anti-AIDS agents. Part 47: synthesis and anti-HIV activity of 3-substituted 3',4'-Di-O-(S)-camphanoyl-(3'R,4'R)-(+)-cis-khellactone derivatives. Bioorg Med Chem Lett. 2001;11(17):2291&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Kashiwada Y., Cosentino L.M., et al. Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. J Med Chem. 1994;37(23):3947&#x2013;3955.</Citation><ArticleIdList><ArticleId IdType="pubmed">7525962</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yuan X., Yu D., Lee K.H., Chen C.H. Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. Virology. 2005;332(2):623&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680427</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia P., Yin Z.J., Chen Y., et al. Anti-AIDS agents. Part 58: synthesis and anti-HIV activity of 1-thia-di-O-(-)-camphanoyl-(+)-cis-khellactone (1-thia-DCK) analogues. Bioorg Med Chem Lett. 2004;14(12):3341&#x2013;3343.</Citation><ArticleIdList><ArticleId IdType="pubmed">15149703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D., Chen C.H., Brossi A., Lee K.H. Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents. J Med Chem. 2004;47(16):4072&#x2013;4082.</Citation><ArticleIdList><ArticleId IdType="pubmed">15267246</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Yu D., Wild C., et al. Anti-AIDS agents. 52. Synthesis and anti-HIV activity of hydroxymethyl (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone derivatives. J Med Chem. 2004;47(3):756&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736256</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Li Y., Smith P.C., et al. Anti-AIDS agents 65: investigation of the in&#xa0;vitro oxidative metabolism of 3',4'-Di-O-(-)-camphanoyl-(+)-cis-khellactone derivatives as potent anti-hiv agents. Drug Metab Dispos. 2005;33(11):1588&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087699</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhang Q., Zhang B., et al. Anti-AIDS agents. Part 56: synthesis and anti-HIV activity of 7-thia-di-O-(-)-camphanoyl-(+)-cis-khellactone (7-thia-DCK) analogs. Bioorg Med Chem. 2004;12(24):6383&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15556756</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.P., Yan G., Guo J.M., et al. Prenylated coumarins from the fruits of Manilkara zapota with potential anti-inflammatory effects and anti-HIV activities. J Agric Food Chem. 2019;67(43):11942&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pubmed">31622090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M., Ma L., Wen J., et al. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase. Eur J Med Chem. 2020;186</Citation><ArticleIdList><ArticleId IdType="pubmed">31771827</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez N., Sancho R., Bedoya L.M., et al. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antivir Res. 2005;66(2&#x2013;3):137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911030</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmedo D., Sancho R., Bedoya L.M., et al. 3-Phenylcoumarins as inhibitors of HIV-1 replication. Molecules. 2012;17(8):9245&#x2013;9257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6268528</ArticleId><ArticleId IdType="pubmed">22858844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo E., Taura M., Matsuda K., et al. Inhibition of HIV-1 replication by a tricyclic coumarin GUT-70 in acutely and chronically infected cells. Bioorg Med Chem Lett. 2013;23(3):606&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">23290051</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda K., Hattori S., Kariya R., et al. Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Biochem Biophys Res Commun. 2015;457(3):288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">25576356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao P.C., Mouscadet J.F., Leh H., Auclair C., Hsu L.Y. Chemical modification of coumarin dimer and HIV-1 integrase inhibitory activity. Chem Pharm Bull (Tokyo) 2002;50(12):1634&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C.C., Mouscadet J.F., Tsai H.J., Liu C.T., Hsu L.Y. Synthesis and HIV-1 integrase inhibition of novel bis- or tetra-coumarin analogues. Chem Pharm Bull (Tokyo) 2007;55(12):1740&#x2013;1743.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057750</ArticleId></ArticleIdList></Reference><Reference><Citation>Olomola T.O., Mosebi S., Klein R., et al. Novel furocoumarins as potential HIV-1 integrase inhibitors. Bioorg Chem. 2014;57:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Cermakova K., De Rijck J., et al. Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proc Natl Acad Sci U S A. 2018;115(30):E7053&#x2013;E7062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065015</ArticleId><ArticleId IdType="pubmed">29997176</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito F., Ambrosio F.A., Maleddu R., et al. Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity. Eur J Med Chem. 2019;182</Citation><ArticleIdList><ArticleId IdType="pubmed">31442684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho R., Marquez N., Gomez-Gonzalo M., et al. Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway. J Biol Chem. 2004;279(36):37349&#x2013;37359.</Citation><ArticleIdList><ArticleId IdType="pubmed">15218031</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng M., Xie L., Zhong L., Liao Y., Liu L., Li X. Imperatorin: a review of its pharmacology, toxicity and pharmacokinetics. Eur J Pharmacol. 2020;879:173124.</Citation><ArticleIdList><ArticleId IdType="pubmed">32339515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P.H., Ke Y.Y., Su C.T., et al. Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway. J Virol. 2011;85(17):9114&#x2013;9126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165834</ArticleId><ArticleId IdType="pubmed">21697490</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikishima Y., Takaishi Y., Honda G., et al. Chemical constituents of Prangos tschiniganica; structure elucidation and absolute configuration of coumarin and furanocoumarin derivatives with anti-HIV activity. Chem Pharm Bull (Tokyo) 2001;49(7):877&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">11456095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv L., Wang Q., Xu Y., et al. Vpr targets TET2 for degradation by CRL4(VprBP) E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Mol Cell. 2018;70(5):961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6071318</ArticleId><ArticleId IdType="pubmed">29883611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Su L. Vpr enhances HIV-1 env processing and virion infectivity in macrophages by modulating TET2-dependent IFITM3 expression. mBio. 2019;10(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703422</ArticleId><ArticleId IdType="pubmed">31431548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong E.B., Watanabe N., Saito A., et al. Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR. J Biol Chem. 2011;286(16):14049&#x2013;14056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077605</ArticleId><ArticleId IdType="pubmed">21357691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan D.H., Pannecouque C., De Clercq E., Chikhalia K.H. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents. Arch Pharm (Weinheim) 2009;342(5):281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">19415671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatma B., Kumar R., Singh V.A., et al. Alphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection. Antivir Res. 2020;179</Citation><ArticleIdList><ArticleId IdType="pubmed">32380148</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver S.C., Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372(13):1231&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">25806915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwu J.R., Kapoor M., Tsay S.C., et al. Benzouracil-coumarin-arene conjugates as inhibiting agents for chikungunya virus. Antivir Res. 2015;118:103&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">25839734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwu J.R., Huang W.C., Lin S.Y., et al. Chikungunya virus inhibition by synthetic coumarin-guanosine conjugates. Eur J Med Chem. 2019;166:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">30703657</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Calderon C., Mesa-Castro C., Robledo S., et al. Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections. BMC Compl Alternative Med. 2017;17(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241984</ArticleId><ArticleId IdType="pubmed">28100218</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Xia Y., Hua L., et al. Functionalized selenium nanoparticles enhance the anti-EV71 activity of oseltamivir in human astrocytoma cell model. Artif Cells Nanomed Biotechnol. 2019;47(1):3485&#x2013;3491.</Citation><ArticleIdList><ArticleId IdType="pubmed">31422717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Zhao Y., Kotecha A., et al. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2019;4(3):414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodman A., Lee K.M., Janissen R., et al. Predicting intraserotypic recombination in enterovirus 71. J Virol. 2019;93(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364027</ArticleId><ArticleId IdType="pubmed">30487277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhang H., Zhu M., Luo Z., Peng Y. MEK1-ERKs signal cascade is required for the replication of Enterovirus 71 (EV71) Antivir Res. 2012;93(1):110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101247</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Zhou V., Pan S., et al. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett. 2005;15(24):5467&#x2013;5473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16199156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Niu Y., Wang C., et al. Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents. Bioorg Med Chem. 2016;24(16):3472&#x2013;3482.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Zhang H., Xu F., et al. Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents. Molecules. 2013;18(5):6057&#x2013;6091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6269873</ArticleId><ArticleId IdType="pubmed">23698055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanini S., Ustianowski A., Pisapia R., Zumla A., Ippolito G. Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention. Infect Dis Clin. 2019;33(4):1045&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">31668190</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster M.A., Hofmeister M.G., Kupronis B.A., et al. Increase in hepatitis A virus infections - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019;68(18):413&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6542191</ArticleId><ArticleId IdType="pubmed">31071072</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer A., Holzmann H., Pischke S., et al. Chronic Hepatitis E is associated with cholangitis. Liver Int. 2019;39(10):1876&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790616</ArticleId><ArticleId IdType="pubmed">31102493</ArticleId></ArticleIdList></Reference><Reference><Citation>Medvedev R., Ploen D., Hildt E. HCV and oxidative stress: implications for HCV life cycle and HCV-associated pathogenesis. Oxid Med Cell Longev. 2016;2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756209</ArticleId><ArticleId IdType="pubmed">26955431</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A., Felmlee D.J. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015;7(12):6716&#x2013;6729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690891</ArticleId><ArticleId IdType="pubmed">26694454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zajac M., Muszalska I., Sobczak A., Dadej A., Tomczak S., Jelinska A. Hepatitis C - new drugs and treatment prospects. Eur J Med Chem. 2019;165:225&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwu J.R., Singha R., Hong S.C., et al. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antivir Res. 2008;77(2):157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">17977606</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyts J., De Clercq E., Singha R., et al. Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates. J Med Chem. 2009;52(5):1486&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">19193060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwu J.R., Lin S.Y., Tsay S.C., De Clercq E., Leyssen P., Neyts J. Coumarin-purine ribofuranoside conjugates as new agent against hepatitis C virus. J Med Chem. 2011;54(7):2114&#x2013;2126.</Citation><ArticleIdList><ArticleId IdType="pubmed">21375337</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay S.C., Hwu J.R., Singha R., et al. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. Eur J Med Chem. 2013;63:290&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">23501114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsay S.C., Lin S.Y., Huang W.C., et al. Synthesis and structure-activity relationships of imidazole-coumarin conjugates against hepatitis C virus. Molecules. 2016;21(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6273635</ArticleId><ArticleId IdType="pubmed">26901180</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang T.J. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809016</ArticleId><ArticleId IdType="pubmed">19399811</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi F., Ikeda S., Tsukamoto Y., et al. Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PloS One. 2019;14(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380541</ArticleId><ArticleId IdType="pubmed">30779774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B.Y., Chai D.P., Wu Y.H., et al. Potential drug targets against hepatitis B virus based on both virus and host factors. Curr Drug Targets. 2019;20(16):1636&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pubmed">31362671</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R.L., Chen C.C., Huang Y.L., et al. Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in&#xa0;vitro. Hepatology. 1996;24(3):508&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">8781315</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.Q., Li J., Huang Y., et al. Lignans from the heartwood of Streblus asper and their inhibiting activities to hepatitis B virus. Fitoterapia. 2012;83(2):303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">22119765</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W., Zhao J., Yang M., et al. A coumarin lignanoid from the stems of Kadsura heteroclita. Bioorg Med Chem Lett. 2015;25(7):1506&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">25736995</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Liu S., Fan X.D., Deng L.Q., Ma W.H., Chen M. Two new coumarin glycosides from Herpetospermum caudigerum. J Asian Nat Prod Res. 2015;17(7):738&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559035</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.X., Mou J.F., Luo Q., et al. Anti-hepatitis B virus activity of esculetin from microsorium fortunei in vitro and in vivo. Molecules. 2019;24(19)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6803987</ArticleId><ArticleId IdType="pubmed">31557836</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Zhou B., Valdes J.D., Sun J., Guo H. Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology. 2019;69(4):1816&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438723</ArticleId><ArticleId IdType="pubmed">30362148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd-Ismail N.K., Lim Z., Gunaratne J., Tan Y.J. Mapping the interactions of HBV cccDNA with host factors. Int J Mol Sci. 2019;20(17)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6747236</ArticleId><ArticleId IdType="pubmed">31480501</ArticleId></ArticleIdList></Reference><Reference><Citation>Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51(3):581&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">19616338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd J., Copaciu R., Yahyabeik A., et al. Characterization of polyclonal antibodies to herpes simplex virus types 1 and 2. J Histotechnol. 2019;42(4):202&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">31680648</ArticleId></ArticleIdList></Reference><Reference><Citation>James C., Harfouche M., Welton N.J., et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265941</ArticleId><ArticleId IdType="pubmed">32514197</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L.W., Pei Y., Zhang Y.J., Wang Y.F., Yang C.R. 7-O-methylkaempferol and -quercetin glycosides from the whole plant of Nervilia fordii. J Nat Prod. 2009;72(6):1057&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">19422205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavrsnik D., Muratovic S., Makuc D., et al. Benzylidene-bis-(4-hydroxycoumarin) and benzopyrano-coumarin derivatives: synthesis, (1)H/(1)(3)C-NMR conformational and X-ray crystal structure studies and in&#xa0;vitro antiviral activity evaluations. Molecules. 2011;16(7):6023&#x2013;6040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6264767</ArticleId><ArticleId IdType="pubmed">21772234</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F., Zhao Z., Ma S., et al. Cnidimonins A-C, three types of hybrid dimer from Cnidium monnieri: structural elucidation and semisynthesis. Org Lett. 2017;19(18):4920&#x2013;4923.</Citation><ArticleIdList><ArticleId IdType="pubmed">28858518</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajtar B., Skalicka-Wozniak K., Swiatek L., Stec A., Boguszewska A., Polz-Dacewicz M. Antiviral effect of compounds derived from Angelica archangelica L. on Herpes simplex virus-1 and Coxsackievirus B3 infections. Food Chem Toxicol. 2017;109(Pt 2):1026&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">28487231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghannadi A., Fattahian K., Shokoohinia Y., Behbahani M., Shahnoush A. Anti-viral evaluation of sesquiterpene coumarins from Ferula assa-foetida against HSV-1. Iran J Pharm Res (IJPR) 2014;13(2):523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157027</ArticleId><ArticleId IdType="pubmed">25237347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittkowsky A.K. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3(3):221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15199454</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng D., Zhang A., Yang Y., Yang P. Coumarin-containing hybrids and their antibacterial activities. Arch Pharm (Weinheim) 2020;353(6)</Citation><ArticleIdList><ArticleId IdType="pubmed">32253782</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon C.D., Jan Y.H., Foster N., et al. Synthetically modified&#xa0;methoxsalen for enhanced cytotoxicity in light and&#xa0;dark reactions. Bioorg Med Chem Lett. 2019;29(4):619&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364570</ArticleId><ArticleId IdType="pubmed">30638875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y., Fujii W., Hori H., Kitagawa Y., Ozaki K. Relationship between coumarin-induced hepatocellular toxicity and mitochondrial function in rats. Food Chem Toxicol. 2016;90:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26806632</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P.J., Lin Z.J., Zhang X.M., Zou L.N., Guo F.F., Zhang B. [Toxicological research and safety consideration of coumarins] Zhongguo Zhongyao Zazhi. 2020;45(3):518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">32237508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>